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Nontyphoidal Salmonellae cause a devastating burden of invasive
disease in sub-Saharan Africa with high levels of antimicrobial re-
sistance. Vaccination has potential for a major global health impact,
but no licensed vaccine is available. The lack of commercial incentive
makes simple, affordable technologies the preferred route for vac-
cine development. Here we compare equivalent Generalized Mod-
ules for Membrane Antigens (GMMA) outer membrane vesicles and
O-antigen-CRM197 glycoconjugates to deliver lipopolysaccharide O-
antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines.
Salmonella strains were chosen and tolR deleted to induce GMMA
production. O-antigens were extracted from wild-type bacteria and
conjugated to CRM197. Purified GMMA and glycoconjugates were
characterized and tested in mice for immunogenicity and ability to
reduce Salmonella infection. GMMA and glycoconjugate O-antigen
had similar structural characteristics, O-acetylation, and glucosylation
levels. Immunization with GMMA induced higher anti–O-antigen IgG
than glycoconjugate administered without Alhydrogel adjuvant.
With Alhydrogel, antibody levels were similar. GMMA induced a di-
verse antibody isotype profile with greater serum bactericidal activ-
ity than glycoconjugate, which induced almost exclusively IgG1.
Immunization reduced bacterial colonization of mice subsequently
infected with Salmonella. S. Typhimurium numbers were lower in
tissues of mice vaccinated with GMMA compared with glycoconju-
gate. S. Enteritidis burden in the tissues was similar in mice immu-
nized with either vaccine. With favorable immunogenicity, low cost,
and ability to induce functional antibodies and reduce bacterial bur-
den, GMMA offer a promising strategy for the development of
a nontyphoidal Salmonella vaccine compared with established
glycoconjugates. GMMA technology is potentially attractive for
development of vaccines against other bacteria of global health
significance.
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Invasive nontyphoidal Salmonella (iNTS) disease is a leadingcause of death and morbidity in developing countries (1–3).
Nontyphoidal Salmonellae are responsible for up to 39% of
community-acquired bloodstream infections in sub-Saharan
Africa with an average case fatality rate of 19% (4). The ef-
fectiveness of antibiotic treatment is hampered by the difficulty
in making a diagnosis, the sudden onset of the disease, and the
growing frequency of multidrug resistance (1, 2, 5). Higher in-
cidence and increased severity of iNTS disease have been ob-
served in young children below 72 mo of age, in patients with
malaria, anemia, malnutrition, HIV, sickle cell disease, and
hemolysis (6–9). Moreover, the Global Burden of Disease
Study 2015 estimated that NTS is the third commonest cause of
diarrheal deaths at 90,300 (95% uncertainty interval, 34,100–
183,100) (10).
Salmonella enterica serovars Typhimurium and Enteritidis are
responsible for 91% of the cases of iNTS disease reported in
Africa (4) and a similar proportion of NTS diarrheal disease. A
bivalent vaccine against these two serovars could represent a
valuable public health intervention. Several groups have been
working on the development of glycoconjugate, protein-based,
vesicle-based, and live attenuated vaccines against NTS (11), but
none has entered clinical trials over the last 16 y. Hence, a licensed
vaccine is still a long way off. This lack of progress relates pri-
marily to the absence of a commercial incentive to develop such
a vaccine. Hence, a technology that could produce large
quantities of an effective vaccine simply and at low cost would
be enormously valuable for advancing a vaccine against this
devastating disease.
The serovar-specific O-antigen (OAg) moiety of Salmonella
lipopolysaccharide (LPS) is the principal target of protective
immunity (12–14). LPS molecules are composed of lipid A
(endotoxin) attached to the 3-deoxy-D-manno-octulosonic acid
(KDO) terminus of the conserved core region, which is linked to
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the variable OAg chain containing serogroup-specific repeating
units. S. Typhimurium and S. Enteritidis OAg repeating units share
a common backbone, consisting of mannose (Man), rhamnose
(Rha), and galactose (Gal). A different 3,6-dideoxy-hexose residue
is linked to Man in the two serovars: abequose (Abe), conferring
O:4 specificity to S. Typhimurium OAg, and tyvelose (Tyv), con-
ferring O:9 specificity to S. Enteritidis OAg. Both repeating units
can be variably glucosylated and O-acetylated (15). Specific anti-
OAg antibodies have been shown to mediate killing (12, 16) and
confer protection against infection in animal models (13, 14, 17, 18).
The current state-of-the-art approach to polysaccharide-based
vaccines is the glycoconjugate approach, where polysaccharide is
covalently linked to a suitable carrier protein, enabling the in-
duction of a T cell-dependent antibody response (19). To date,
glycoconjugates have been the technology of choice for vaccine
development against iNTS disease (11, 20). We have previously
shown that O-antigen conjugated to the nontoxic recombinant
form of the diphtheria toxin, CRM197, is immunogenic and re-
duces the tissue burden of Salmonella infection in mice (13, 21–
23). However, glycoconjugate vaccines can be both expensive
and complex to produce, particularly when multiple valencies are
necessary, and require large capital investment on infrastructure.
These represent major disadvantages for a vaccine that has no
commercial high-income country application and where the final
manufacturer is likely to be a developing country vaccine man-
ufacturer with limited available expertise compared with large
multinational vaccine companies.
As an alternative strategy to global health vaccines, we are
pioneering the use of an outer membrane vesicle technology
known as Generalized Modules for Membrane Antigens
(GMMA). GMMA technology can be employed as a vehicle to
deliver Salmonella lipopolysaccharide O-antigen to the immune
system. GMMA represent a straightforward technology with the
advantages of low-cost, high-production yields and ease of
technology transfer to the end manufacturer (24, 25).
The integrity and attachment of the inner and outer bacterial
cell wall membranes of Salmonella can be altered by disruption of
the Tol-Pal system, through deletion of the tolR gene (26, 27),
resulting in the release of large quantities of GMMA. GMMA are
outer membrane vesicles of homogeneous size, typically in the
range 40–250 nm, released from the surface of genetically mu-
tated Gram-negative bacteria (24). GMMA constitute an enriched
source of outer membrane antigens, including OAg, presented to
the immune system in their native conformation. GMMA are
optimally sized for uptake by antigen-presenting cells and have
self-adjuvanting activity, delivering innate signals through toll-like
receptor (TLR) ligands and other pathogen-associated molecular
patterns. Unlike live attenuated vaccines, there is no possibility of
infection. Work to date indicates that GMMA are highly immu-
nogenic (28–31), but so far there has been no direct comparison of
immunogenicity with equivalent glycoconjugate vaccines.
The aims of this study were to: (i) generate and characterize a
bivalent GMMA and bivalent glycoconjugate vaccine against
S. Typhimurium and S. Enteritidis, as alternative approaches to
developing a vaccine against iNTS disease; and (ii) compare the
immunogenicity and ability of the two vaccines to reduce the
bacterial burden following infection with Salmonella in mice, to
down-select a vaccine strategy for clinical development.
Results
OAg-CRM197 Conjugates. S. Typhimurium and S. Enteritidis OAg,
purified from 2189 and 618 wild-type bacteria (21), were in-
dependently linked to CRM197 as carrier protein. Terminal link-
age of the sugar chains to the protein was selected in order not to
impact on OAg chain structure and epitopes (22). Both conjugates
were characterized by an OAg-to-protein weight ratio close to 2
(1.9 for S. Typhimurium OAg-CRM197 and 2.3 for S. Enteritidis
OAg-CRM197), with <20% free saccharide. Analysis by HPLC-SEC
(SI Appendix, Fig. S1) indicated the higher–molecular-weight
peak expected for the conjugates, compared with unconjugated
protein, and no detectable presence of unreacted CRM197.
S. Typhimurium OAg-CRM197 was characterized by a more
polydisperse population compared with S. Enteritidis OAg-
CRM197. This is likely due to the presence of two different pop-
ulations in 2189 wild-type OAg (average size of 80.8 and 31.6 kDa),
compared with just one population of relatively lower molecular
weight for 618 wild-type OAg (average size of 29.6 kDa).
GMMA.GMMA were produced from ΔtolR mutants of the same
strains used as the source of OAg for the glycoconjugate vac-
cine (26). S. Typhimurium and S. Enteritidis GMMA had
similar size and OAg-to-protein weight ratio (0.72 and 0.61,
respectively) (Table 1). The amount of lipid A per mg of pro-
tein was higher for S. Enteritidis compared with S. Typhimurium
GMMA (Table 1).
Characterization of OAg on GMMA and Free OAg for Conjugation to
CRM197. OAg is the main target for the immune response against
both NTS GMMA and glycoconjugate vaccines. Therefore, the
structural characteristics of OAg purified from wild-type bacteria
for the synthesis of glycoconjugates and presented on GMMA
from corresponding ΔtolRmutated strains were fully investigated
and compared. Both S. Typhimurium and S. Enteritidis OAg
from GMMA showed similar sugar composition, O-acetylation,
and glucosylation levels to OAg from corresponding wild-type
bacteria (Table 2). S. Enteritidis OAg were also similar for
molecular size distribution, with OAg on GMMA showing an
additional shoulder at higher molecular weight compared with
S. Enteritidis wild-type OAg. For S. Typhimurium, OAg on
GMMA was characterized as being one main population, while
an additional population at relatively higher molecular weight
was observed with OAg from wild-type bacteria (Fig. 1).
Immunogenicity Studies in Mice. GMMA and OAg-CRM197 con-
jugates were compared in mice at a 10-fold increasing range of
OAg doses (1 ng to 10 μg for GMMA and 0.1–10 μg for OAg-
CRM197, as OAg equivalents), all formulated with Alhydrogel
(Fig. 2). Formulations of both GMMA and conjugates at 1 μg
OAg dose were also tested without Alhydrogel to assess the
Table 1. Characterization of GMMA particles
Characteristic
S. Typhimurium
GMMA
S. Enteritidis
GMMA
Percent soluble proteins <5 <5
Particle size [weight average geometric
radius (Rw) nm by multiangle light
scattering]
38.4 39.1
Particle size (radius nm by trasmission
electron microscopy)
22.5 22.5
OAg/protein wt/wt ratio 0.72 0.61
nmol lipid A/mg protein 107 157
Table 2. Sugar composition analysis of OAg on GMMA (from
ΔtolR bacteria) and from wild-type bacteria for conjugation
to CRM197
Molar ratio to Rha
OAg from Tyv/Abe Man Gal % Glc % OAc
Salmonella Typhimurium
Wild type 0.95 1.01 1.09 51 58
GMMA 1.00 0.83 1.18 39 53
Salmonella Enteritidis
Wild type 0.95 0.95 1.05 19 16
GMMA 1.00 0.99 1.12 24 4
Sugar composition analysis by HPAEC-PAD, but Tyv/Abe quantification
and O-acetylation by 1H NMR.
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impact of Alhydrogel on immune response. For S. Typhimurium,
GMMA induced a significantly higher anti-OAg IgG response
at day 42 than conjugate at all tested doses (P ≤ 0.007 for all
comparisons) (Fig. 2A). For S. Enteritidis, the anti-OAg IgG
response induced by GMMA was similar to that induced by the
conjugate at day 42 for all tested OAg doses and only signifi-
cantly higher with the GMMA 10 μg OAg dose at day 28 (P =
0.002) (Fig. 2B).
Both for S. Typhimurium and S. Enteritidis GMMA, a dose–
response was observed (Spearman rank correlation, day 42 sam-
ples: ρ = 0.839 and P < 0.0001 for S. Typhimurium; ρ = 0.879 and
P < 0.0001 for S. Enteritidis). A rise in antibody titer following the
second vaccine dose was observed for both GMMA (P = 0.008 in
the range 0.1–10 μg dose for both S. Typhimurium and
S. Enteritidis) and conjugates (P = 0.04 at 0.1 and 10 μg dose and
P = 0.008 at 1 μg dose for S. Typhimurium; P = 0.008 at all doses
tested for S. Enteritidis). When mice were immunized with
S. Typhimurium GMMA in the absence of Alhydrogel, anti-OAg
IgG response was higher than with Alhydrogel (P = 0.005 at day
42). With S. Enteritidis GMMA, addition of Alhydrogel did not
affect the immune response (P = 0.5 at day 42). For both
S. Typhimurium and S. Enteritidis conjugates at 1 μg dose, no IgG
response was detected in the absence of Alhydrogel (at day 42,
P = 0.0005 and P < 0.0001, respectively).
Day 42 pooled sera for each group were tested for functional
activity. Serum bactericidal assay (SBA) titers induced by GMMA
were higher than those induced by conjugates for both S. Typhi-
murium and S. Enteritidis, (Fig. 2 C and D). Sera from mice im-
munized with S. Typhimurium GMMA at 1 μg OAg dose were
75-fold times more bactericidal than sera from mice immunized
with the corresponding conjugate at the same OAg dose. There was
a 20-fold difference when comparing bactericidal titers of sera from
S. Enteritidis GMMA and conjugate at 1 μg OAg dose. Sera from
mice immunized with very low amounts of GMMA (1–10 ng OAg)
also showed bactericidal activity. Alhydrogel did not increase SBA
titers induced by the GMMA vaccines, whereas it enhanced those
induced by the glycoconjugates (26-fold difference for S. Typhi-
murium and 18-fold difference for S. Enteritidis conjugates).
To better understand the reason for the differences observed,
analysis of IgG subclasses and IgM was performed. Day 42 sera
from mice immunized with GMMA and conjugate vaccines, at
1 μg OAg dose with Alhydrogel, were compared. IgG induced by
the conjugates was almost exclusively IgG1, particularly for
S. Enteritidis conjugate, with sera containing undetectable levels
of OAg-specific IgG2a, IgG2b, and IgG3 (SI Appendix, Fig. S2).
In contrast, GMMA induced all IgG subclasses, with the ex-
ception of IgG2a for S. Enteritidis. S. Enteritidis and S. Typhi-
murium GMMA induced significantly higher anti–OAg-specific
IgG2b (P = 0.0006 for S. Typhimurium and P = 0.0014 for
S. Enteritidis) and IgG3 (P = 0.0003 for S. Typhimurium and P =
0.0014 for S. Enteritidis) than conjugates. GMMA also induced
anti-OAg IgM antibodies, which were undetectable in sera of mice
immunized with conjugate vaccines (SI Appendix, Fig. S2).
Based on these immunogenicity results and with the aim of de-
veloping a vaccine against both S. Typhimurium and S. Enteritidis,
bivalent formulations of GMMA and conjugates at 1 μg OAg dose
were further tested in mice. In this second study, bivalent GMMA
and OAg-CRM197 formulations induced similar S. Typhimurium
and S. Enteritidis anti–OAg-specific IgG responses (at day 42, P =
0.07 for S. Typhimurium and P = 0.14 for S. Enteritidis) (Fig. 3 A
and B). SBA performed with day 42 individual mouse sera showed
markedly higher SBA titers following immunization with GMMA
compared with conjugates (P = 0.008 and 0.0001 for S. Typhimu-
rium and S. Enteritidis strains, respectively). Many sera from mice
immunized with conjugate vaccines (17 out of 24) did not show any
bactericidal activity (Fig. 3 C and D).
To compare the in vivo efficacy of GMMA and conjugate vac-
cines, we performed a Salmonella infection study in mice immu-
nized with bivalent formulations of either vaccine. After challenge
with invasive strains of S. Typhimurium or S. Enteritidis, mice im-
munized with either bivalent GMMA or conjugate vaccines showed
reduced bacterial colonization of the spleen and liver compared
with control mice. The GMMA vaccine resulted in lower bacterial
cfus than conjugates (Fig. 3 E and F) in liver (P = 0.009), although
there was no significant difference in spleen after infection with
S. Typhimurium. There was no difference in bacterial counts be-
tween mice immunized with S. Enteritidis GMMA and conjugates.
Discussion
In this study, we have compared glycoconjugate and GMMA OAg-
based approaches to the development of a vaccine against iNTS
disease. In view of the coendemicity of S. Typhimurium and
S. Enteritidis in Africa, a bivalent vaccine covering both serovars is
an obvious strategy (23). For this reason, we compared monovalent
and bivalent GMMA and glycoconjugate formulations. The
GMMA were able to (i) induce (a) high anti–OAg-specific IgG
responses in mice, (b) broad IgG subclass and Ig isotype profile,
and (c) strong bactericidal activity, and (ii) reduce bacterial colo-
nization in mice infected with virulent endemic strains. The bivalent
OAg-CRM197 conjugate formulation induced immune responses
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Fig. 1. HPLC-SEC chromatograms of OAg chains extracted from GMMA and compared with OAg purified from corresponding wild-type bacteria. SEn,
S. Enteritidis; STm, S. Typhimurium.
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similar to the single-conjugate components, confirming previous
results (23). Here we have gone on to demonstrate that the vaccine
reduces bacterial colonization in mice following infection.
We found that GMMA and glycoconjugates induced similar
anti-OAg IgG responses when administered with Alhydrogel.
IgG levels induced by GMMA were high, irrespective of the
presence of Alhydrogel, while conjugates were unable to induce
a response without Alhydrogel. This lack of immunogenicity with
unadjuvanted conjugates is in contrast with our previous findings
and may be related to the lower OAg-equivalent dose used in the
current study compared with previous studies (23) and to the
different immunization schedule used, with two doses at days
0 and 28 compared with three doses at 2-wk intervals (21). In
general, GMMA were able to induce higher serum bactericidal
titers than conjugates, with sera from around 70% of conjugate-
immunized mice unable to kill Salmonella.
Considering the impact that OAg structural modifications (sac-
charide size, O-acetylation, and glucosylation level) can have on the
immune responses (13, 21), OAg from wild-type bacteria used to
synthesize the glycoconjugates and OAg from the GMMAwere fully
characterized, and no major differences were identified. Therefore,
OAg structure is unlikely to be a factor responsible for the difference
in immunogenicity in mice between the two vaccine approaches. A
more plausible factor is the different antibody class and subclass
profile elicited, with GMMA inducing higher specific IgG2b, IgG3,
and IgM levels than the glycoconjugate, which, in contrast, elicited
IgG1 only. IgG2a and IgG2b are known to bind complement
component C1q more efficiently than IgG1 (32), and IgM is the
most bactericidal of all antibody classes. Another factor to account
for the difference in immunogenicity and bactericidal activity is that
GMMA may constitute a more immunogenic format for presenting
OAg to the immune system. GMMA likely exert a self-adjuvanting
effect. They also have the advantage of presenting multiple antigens
to the immune system with the potential to induce killing through
various effector mechanisms (complement-, phagocyte-, and T cell-
mediated) directed at outer membrane proteins as well as OAg.
In the infection study, prior immunization with bivalent
GMMA vaccine reduced the S. Typhimurium load more than
corresponding glycoconjugate, but there was no difference be-
tween conjugates and GMMA in relation to S. Enteritidis counts.
This finding may be partly explained by our previous observation
that S. Enteritidis isolates are less susceptible to antibody-
dependent complement-mediated killing than S. Typhimurium
isolates (33). Hence, bactericidal activity of anti-OAg antibodies
may be more critical for killing S. Typhimurium than S. Enter-
itidis. Other immune effector mechanisms, including antibody-
mediated phagocytosis (34) and CD4+ and CD8+ T cell mecha-
nisms, may be of greater importance for killing S. Enteritidis.
A potential concern with the use of GMMA vaccines is their
reactogenicity, since GMMA contain LPS (34). Therefore, we
have engineered S. Typhimurium and S. Enteritidis GMMA
with reduced reactogenicity while maintaining adjuvanticity by
modifying the LPS lipid A acylation pattern (26). A similar
detoxification strategy was employed for our most advanced
GMMA-based vaccine, a Shigella sonnei GMMA vaccine, which
was well-tolerated in clinical trials (25, 29, 30). In the current
Fig. 2. S. Typhimurium and S. Enteritidis GMMA and glycoconjugate vaccines compared in mice as monovalent formulations. Eight C57BL/6 mice per group
were s.c. immunized at days 0 and 28, with different OAg doses on Alhydrogel. (A and B) Summary graphs of anti-OAg IgG geometric mean units (bars) and
individual antibody levels (dots). (C and D) Serum bactericidal assay (SBA) titers of pooled sera from day 42 from each group against S. Typhimurium D23580
or S. Enteritidis CMCC4314 strains. SEn, S. Enteritidis; STm, S. Typhimurium.
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study, we tested GMMA without modified lipid A structure. However,
we have shown previously that introduction of genetic manipulations
to reduce Salmonella GMMA reactogenicity, including pagP
and msbB deletions, does not significantly impact anti–OAg-
specific IgG response or ability of postvaccination sera to kill
bacteria in vitro (28). While we have verified that use of Alhydrogel
does not enhance immunogenicity induced in mice by GMMA, for-
mulation with Alhydrogel is required for abrogation of pyrogenicity in
Fig. 3. In vivo infection study in mice immunized with GMMA and conjugate in bivalent formulation. Twelve C57BL/6 mice per group were s.c. immunized at days
0 and 28 at 1 μg OAg/dose per each antigen with Alhydrogel. Seventeen days after the second injection, six mice of each groupwere challenged intraperitoneally with
104 cfu of S. Typhimurium D23580 or with S. Enteritidis D24954. Twenty-four hours after challenge, mice were killed and spleens and livers collected for bacterial plate
counting. (A and B) Summary graphs of anti-OAg IgG geometric mean units (bars) and individual antibody levels (dots). (C and D) SBA titers of single sera
collected at day 42 from each group against S. Typhimurium D23580 or S. Enteritidis CMCC4314 strains. (E and F) Bacterial cfu measured in spleens and livers
postchallenge. SEn, S. Enteritidis; STm, S. Typhimurium.
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rabbits (35). For this reason, GMMA and conjugates were for the
most part compared when coadministered with Alhydrogel.
A key advantage of GMMA over conjugates is the simplicity
and cost-effectiveness of the production process, making the
GMMA approach particularly attractive for global health vaccines
for low- and middle-income countries, where high cost of manu-
facture can be an obstacle to vaccine implementation (36, 37).
Production yields are high, and following fermentation of the
GMMA-producing bacterial strains, two simple tangential flow
filtration steps allow a high level of purification of GMMA. These
factors all contribute to potential very low cost of goods for
GMMA vaccines, another critical factor for vaccines designed
primarily for global health application.
In conclusion, we have designed equivalent bivalent S. Typhi-
murium and S. Enteritidis GMMA and glycoconjugate vaccines.
By testing these vaccines in mice, we have demonstrated that the
GMMA approach confers equal or enhanced immunogenicity and
ability to reduce bacterial load compared with the standard
glycoconjugate approach. Given the added advantages of simplicity
of production and low cost of goods, these findings indicate that
the GMMA strategy has excellent potential. GMP lots of the GMMA
vaccine have now been produced with a view to an in-human study
in the near future.
This is a direct comparison of the GMMA and glycoconjugate
vaccine strategies for bacterial vaccines. Therefore, it will be im-
portant to determine whether the GMMA approach offers the
same advantages for development of vaccines against other bac-
terial diseases. Similar comparative vaccinology studies should be
conducted for other Gram-negative bacteria, which are particu-
larly amenable to genetic manipulation for GMMA production.
Materials and Methods
SI Appendix, Materials and Methods feature additional information to the
section provided here.
GMMA were produced from S. Typhimurium 2189 ΔtolR and from
S. Enteritidis 618 ΔtolR strains (SI Appendix, Materials and Methods) and
purified and characterized as previously described (26, 28, 38). For synthesis
of glycoconjugates, OAg were purified from the same S. Typhimurium 2189
and S. Enteritidis 618 wild-type bacteria (21, 39) and characterized as pre-
viously described (15, 39). OAg chains isolated from GMMA were charac-
terized by using the same methods for OAg from wild-type bacteria (15, 28).
For conjugation to CRM197 (provided by GSK Vaccines), OAg was derivatized
with adipic acid dihydrazide (ADH) by reductive amination of the KDO ter-
minal sugar and linked to the amino groups on the protein after attachment
of a second linker, adipic acid bis(N-hydroxysuccinimide) (SIDEA), to ADH (40).
Conjugation conditions and assays for characterization of OAg-CRM197 conju-
gates and intermediates were as previously described (13, 21–23). Two studies
in mice were conducted to compare the immunogenicity of S. Typhimurium
and S. Enteritidis GMMA and glycoconjugates. Details on the immunization
schemes and sera analysis are reported in SI Appendix,Materials and Methods.
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